Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Lapaquistat Acetate in Type 2 Diabetes with Dyslipidemia
NCT00251680Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2005
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia comparing Lapaquistat Acetate 50 mg QD with Placebo (2 arms). Primary endpoint: Low Density Lipoprotein cholesterol at Week 24. Started Oct 2005; status: completed.
02
Drugs
lapaquistat
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT00251680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251680.